One of the most known innovators in the medical device industry is DePuy Orthopaedics which has Johnson & Johnson as its parent company. Geared towards younger and more active patients, the company was among the first to develop metal-on-metal hip replacement devices. DePuy  hip replacements were placed on the market before consumers knew of the risks associated with these products because DePuy was able to avoid pre-market clinical trials. As a result, complaints associated with the Pinnacle device include post surgical complications and failure rates in 12-13% of recipients. As an effect, complaints surfaced and lawsuits have been filed. The same thing is also going on in Australia as they are also experiencing hip replacementfailures.

Blood clots in the lower extremities that can travel to the lungs and cause a pulmonary embolism is one of the post surgical risks from hip replacement surgery. Although rare, severe cases of pulmonary embolism can cause respiratory failure and shock. Other complications include difficulty in urination, local skin or joint infection, fracture of the bone during and after surgery, scarring, and limitation of the range of motion of the hip. The common risks associated with anesthesia use include heart arrhythmias, liver toxicity, and pneumonia as with any surgery requiring anesthesia.

The majority of complaints received by the U.S. Food andDrug Administration (FDA) regarding the Pinnacle hip replacement focused on the premature loosening of the device from the bone, leading to failure of the device. Within five years after their initial hip replacement surgery, it has been reported that one out of eight patients will need to undergo corrective surgery.

DePuy Orthopaedics and Johnson & Johnson are currently facing a lot of things and not just these people filing for a DePuy Pinnacle HipReplacement Lawsuit. With the allegations against their different products such as Tylenol, Risperdal, and the DePuy ASR Acetabular XL Hip Replacement system, a lot of challenges are in their sleeves.